The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CMND | -90.21% | N/A | N/A | -100% |
| S&P | +12.66% | +85.37% | +13.13% | +53% |
Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The firm intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.
No news articles found for Clearmind Medicine.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 17.6% |
| Market Cap | $3.17M | -39.8% |
| Net Income | -$1.31M | 37.3% |
| EBITDA | -$1.40M | 4.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.50M | -54.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.03M | -19.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -66.77% | 66.5% |
| Return On Invested Capital | -101.43% | -18.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.15M | -4.2% |
| Operating Free Cash Flow | -$1.15M | -4.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.59 | 1.89 | 1.66 | 2.23 | 17.30% |
| Price to Tangible Book Value | 1.65 | 1.96 | 1.73 | 2.34 | 18.86% |
| Enterprise Value to EBITDA | 0.56 | -0.22 | -0.36 | -1.34 | -214.42% |
| Return on Equity | -256.9% | -125.6% | -139.2% | -178.6% | -33.32% |
| Total Debt | $0.05M | $0.05M | $0.04M | $0.03M | -53.30% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
